EGFR and interstitial lung disease: A 60‐year‐old woman with stage IVB EGFR‐mutated lung adenocarcinoma and prior brain metastases was initially treated with osimertinib but discontinued therapy after developing CTCAE grade 2 interstitial lung disease (ILD).